Fiorenzo Villani net worth and biography

Fiorenzo Villani Biography and Net Worth

Insider of Portage Biotech

Founder of Alpha Compute Corp. (Nasdaq: ALP). Co-founder of Nasdaq Corporate Solutions, Managing Director of Strategy at Nasdaq. Chief Strategy Officer of Transform Group. MBA from Cornell.

What is Fiorenzo Villani's net worth?: The estimated net worth of Fiorenzo Villani is at least $193.59 thousand as of September 22nd, 2026. Villani owns 48,886 shares of Portage Biotech stock worth more than $193,589 as of October 7th. This net worth estimate does not reflect any other investments that Villani may own. Learn More about Fiorenzo Villani's net worth.
How do I contact Fiorenzo Villani?: The corporate mailing address for Villani and other Portage Biotech executives is 6 ADELAIDE ST. EAST, SUITE 300, TORONTO, Ontario, Canada, M5C 1H6. Portage Biotech can also be reached via phone at (416) 737-7600 and via email at [email protected]. Learn More on Fiorenzo Villani's contact information.
Has Fiorenzo Villani been buying or selling shares of Portage Biotech?: Fiorenzo Villani has not been actively trading shares of Portage Biotech during the last ninety days. Most recently, on Tuesday, September 22nd, Fiorenzo Villani bought 10,000 shares of Portage Biotech stock. The stock was acquired at an average cost of $4.40 per share, with a total value of $44,000.00. Following the completion of the transaction, the insider now directly owns 48,886 shares of the company's stock, valued at $215,098.40. Learn More on Fiorenzo Villani's trading history.
Who are Portage Biotech's active insiders?: Portage Biotech's insider roster includes Brittany Kaiser (CEO), and Fiorenzo Villani (Insider). Learn More on Portage Biotech's active insiders.
Are insiders buying or selling shares of Portage Biotech?: In the last year, Portage Biotech insiders bought shares 8 times. They purchased a total of 51,897 shares worth more than $235,245.49. The most recent insider tranaction occured on September, 22nd when insider Fiorenzo Villani bought 10,000 shares worth more than $44,000.00. Learn More about insider trades at Portage Biotech.
Information on this page was last updated on 9/22/2026.

Fiorenzo Villani Insider Trading History at Portage Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/22/2026	Buy	10,000	$4.40	$44,000.00	48,886
9/16/2026	Buy	4,265	$4.05	$17,273.25	38,886
9/15/2026	Buy	10,382	$4.07	$42,254.74	34,601
9/15/2026	Buy	7,900	$4.15	$32,785.00	11,917
9/14/2026	Buy	2,000	$4.16	$8,320.00	24,219
9/9/2026	Buy	7,000	$5.07	$35,490.00	22,219

Fiorenzo Villani Buying and Selling Activity at Portage Biotech

Portage Biotech Company Overview

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

Today's Range

Now: $3.96

$3.75

$4.40

50 Day Range

MA: $6.84

$3.71

$9.95

2 Week Range

Now: $3.96

$3.20

$690.00

Volume

766,203 shs

Average Volume

227,293 shs

Market Capitalization

$6.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63